Kabuki syndrome is a rare autosomal dominant condition characterized by facial features, various organs malformations, postnatal growth deficiency and intellectual disability. The discovery of frequent germline mutations in the histone methyltransferase KMT2D and the demethylase KDM6A revealed a causative role for histone modifiers in this disease. However, the role of missense mutations has remained unexplored. Here, we expanded the mutation spectrum of KMT2D and KDM6A in KS by identifying 37 new KMT2D sequence variants. Moreover, we functionally dissected 14 KMT2D missense variants, by investigating their impact on the protein enzymatic activity and the binding to members of the WRAD complex. We demonstrate impaired H3K4 methyltransferase activity in 9 of the 14 mutant alleles and show that this reduced activity is due in part to disruption of protein complex formation. These findings have relevant implications for diagnostic and counseling purposes in this disease.
Introduction
Kabuki syndrome (KS, MIM #147920, MIM #300867) is a rare autosomal dominant condition characterized by striking facial features such as elongated palpebral fissures with eversion of the lateral third of the lower eyelid, short columella with depressed nasal tip, skeletal anomalies, dermatoglyphic abnormalities, mild to moderate intellectual disability and postnatal growth deficiency (1, 2) . Additional findings include congenital heart defects, genitourinary anomalies, cleft lip and/or palate, susceptibility to infections, gastrointestinal abnormalities, ophthalmologic defects, ptosis and strabismus, dental anomalies (including widely spaced teeth and hypodontia), ear pits, visceral abnormalities and premature thelarche (3) . In 2010, whole-exome sequencing successfully identified heterozygous loss of function mutations in the KMT2D gene (MIM #602113, NM_003482.3, also known as MLL2 and MLL4) as the major cause of KS (4) . KMT2D encodes a conserved member of the SET1 family of histone lysine methyltransferases (KMTs), which catalyzes the methylation of lysine 4 on histone H3 (H3K4), a modification associated with active transcription (5-7). The enzymatic function of KMT2D depends on a cluster of conserved C-terminal domains, including plant homeodomains (PHD), two phenylalanine and tyrosine (FY)-rich motifs [FY-rich, N-terminal (FYRN) and FY-rich, C-terminal (FYRC)] and a catalytic Su(var)3-9, Enhancer-of-zeste, Trithorax (SET) domain. In mammalian cells, KMT2D functions as a major histone H3K4 mono-/di-/trimethyltransferase (8) (9) (10) (11) (12) (13) (14) (15) that is required for the epigenetic control of active chromatin states in a tissue-specific manner (16) .
In addition to KMT2D mutations, a subset of KS individuals has been identified with either point mutations or microdeletions encompassing the X-linked gene, KDM6A (MIM #300128, NM_021140.3, also known as UTX) (17) (18) (19) , which encodes for a Histone H3 lysine-27 demethylase. KDM6A plays a crucial role in chromatin remodeling (20, 21) and interacts with KMT2D in a conserved SET1-like complex (16) .
More than 600 KMT2D mutations have been identified so far in KS patients; roughly 84% of them are truncating events (22) including non-sense, indels, small duplications, splice-site, and frameshift mutations, while the remaining 16% are represented by missense variants whose pathogenicity has not been investigated. As a consequence, the interpretation of missense mutations has remained a challenging problem in genetic diagnosis and counseling.
Here we surveyed a cohort of 505 KS patients to expand the mutation spectrum of KMT2D and KDM6A, and investigated the functional impact of missense mutations in the pathogenesis of the disease.
Results

Mutation screening of KMT2D and KDM6A
To expand the spectrum of mutations targeting KMT2D and KDM6A in KS, we integrated our mutation database with mutational screening of 202 newly diagnosed KS patients for a total of 505 cases, by using Sanger sequencing and/or multiplex ligation-dependent probe amplification (MLPA) of the KMT2D coding sequence, followed by KDM6A analysis in patients resulted as KMT2D-negative. We identified a total of 208 KMT2D variants distributed in 196/505 (39%) patients, including 37 that have not been described before (Table 1) . These included 54 non-sense mutations (26%), 59 frameshift mutations (28%), 69 missense mutations (33%), 13 splice site variants (6%), 12 indels (6%) and 1 gross deletion (Table 1) . Missense mutations were distributed across the entire length of the KMT2D gene (Fig. 1A) and were represented by 8 missense variants (11%) localized within the PHD 1-6 domains, one change (1%) in the Coiled Coil/ Poly Q region, 25 variants (36%) localized within the C-terminal of the protein (amino acid 4507-5537) and 36 (52%) variants localized outside of known domains and/or in uncharacterized portions of the protein. Among the KMT2D variants identified, 66 occurred de novo and 32 were inherited from an apparently asymptomatic parent, whereas for the remaining 110 variants we had no access to parental DNA.
Moreover, we identified 14 KDM6A variants; 12 of those were predicted to be pathogenic based on publicly available algorithms (see Materials and Methods) and 7 were never described previously. Seven of the variants were de novo, while for the remaining ones the inheritance was unknown. Thus, 210/505 (41%) KS patients in our cohort carried genetic alterations in one of these two genes; the underlying event in the remaining 295 cases remains unknown (see Discussion).
Pathogenic assessment of missense mutations by bioinformatics tools
Analogous to previous studies, most KMT2D variants in KS are inactivating truncating events that render the protein functionally defective due to the loss of the catalytic SET activity. However, $30% (69/208) of the mutations found in our data set, and 100 of 621 (16.1%) mutations from a recently published mutational analysis review (22) , are in-frame amino acid changes that affect various residues along the KMT2D protein. Table 2 ).
To further assess how KMT2D missense variants may affect protein function/activity, a combination of structure-based methods was employed. Since KMT2D is a multi-domain protein too large to be accurately modeled using computational methods, we aimed to predict and analyze the individual structures of single KTM2D domains. Three-dimensional models were obtained for the ZF-7, FYR and SET domains (QMEAN scores of 0.63, 0.68 and 0.73, respectively) of the human KMT2D (see Materials and Methods for details). Moreover, a crystal structure at 1.4 Å resolution of the WIN domain was retrieved from the Protein Data Bank. Eight missense variants were analyzed to test their effects on protein stability (DDG) and change in total charge (DCharge). The analysis showed that all eight variants target highly conserved regions/residues within these domains (Supplementary Material, Fig. S1 ) and are expected to significantly alter their structure (Supplementary Material, Fig. S2 ). In particular, with one exception (p.H5059P, which falls on the N-terminal residue of the predicted ZF-PHD7 and can be poorly analyzed), all variants were predicted to alter the total charge of the domain and/or the protein stability (Supplementary Material, Fig. S3 ). These data suggest that the missense variants located in the ZF-PHD7, FYR, WIN and SET domains affect the normal structure of the KMT2D protein and may thus potentially alter/impair the protein function.
Missense variants impair KMT2D methyltransferase activity
To experimentally test the functional impact of KS-associated KMT2D missense variants, we generated FLAG-tagged versions of 14 representative KMT2D mutant alleles that harbor amino acid changes in both functional N-terminal and C-terminal domains of the protein including PHD 4-5-6-7, FYRN, WIN and SET domains, using the FUSION-KMT2D construct as template (see Materials and Methods) (Fig. 1B) . c.11843_11860del
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Inherited P ex 39 c.11854_11874dup The 14 tested missense variants have been selected as representative of the entire set of variants identified in our KS cohort that harbor amino acid changes in both N-terminal and C-terminal domains of the protein including PHD 4-5-6-7, FYRN, WIN and SET domains. This construct was selected because the protein encoded by the FUSION-KMT2D wild-type vector retains dose-dependent mono, di and tri methyltransferase activity in vitro to the same extent of a full-length wild-type protein (Supplementary Material, Fig. S4 ), while guaranteeing higher transfection efficiency (not shown).
We measured the ability of the mutated proteins to catalyze mono-, di-and tri-methylation of H3K4 (H3K4me1, me2 and me3) in vitro, using purified nucleosomal histones as substrate and western blot analysis with antibodies directed against these three histone marks. In this assay, 9/14 missense variants led to heterogeneous but significant impairment in H3K4 monomethylation, compared with wild-type KMT2D (range 30-80%), with two additional mutants showing borderline effects ( Fig. 2A  and B) . Additionally, six of the nine mutations were associated with reduced H3K4me2, and 6 with reduced H3K4me3 levels ( Fig. 2A and B) .
To independently confirm the reduced H3K4 trimethyltransferase activity, we used a more sensitive epigenetic EGFP reporter system that specifically monitors this modification (23) (Fig. 2C) . Fluorescence data confirmed the significantly reduced ability to catalyze H3K4me3 for all 6 missense variants tested (on average, $50% compared with the KMT2D wild-type counterpart) (Fig. 2D) . Together, these data indicate that, to various extents, a subset of KS-associated missense mutations can inactivate the function of KMT2D, analogous to truncating mutations.
KMT2D-complex protein interaction
ASH2L and RbBP5 interact with KMT2D co-regulating the expression of target genes (24, 25) . To determine whether KMT2D missense variants affect its function by altering the interaction with ASH2L and RbBP5, we immunoprecipitated protein lysates from HEK 293T cells co-transfected with Flag-tagged FUSION-KMT2D constructs and vectors expressing either ASH2L or RbBP5. Western blot analysis of immunoprecipitated cell lysates showed that the missense variants located at the C-terminal of the protein (p.H5059P, p.T5098P, p.G5189R, p.W5217R, p.R5340Q, p.E5425K p.R5471M and Y5510D) exhibit a weaker interaction with both ASH2L and RbBP5, while p.E1391K and p.F5034V only distressed the interaction between KMT2D and ASH2L, when compared with the wild-type construct. The missense variants p.I1428T and p.Q1522R exhibited an increased interaction with both ASH2L and RbBP5, while the p.M1417V and p.S1476C only increased the interaction of KMT2D with ASH2L (Fig. 3A) .
Combined conformational 3D modeling and free energy interaction variations (see Supplementary Material, Fig. S2 ) indicated that the p.R5340Q missense variant-in the WIN motif of KMT2D-alters the protein domain structure, changing an evolutionarily conserved amino acid position expected to tolerate Arginine and minimally Methionine (Fig. 3B, left) . Since the KMT2D WIN motif (5337-5342) is necessary for the interaction with the WDR5 protein (26), we used transient transfection/coimmunoprecipitation assays to assess whether p.R5340Q alters the ability of KMT2D [expressed as an Myc-tagged green fluorescent protein (GFP) fusion] to physically bind a Flag-tagged WDR5 protein.
As shown in Figure 3B , western blot analysis of FLAGimmunoprecipitates using anti-Myc antibodies showed efficient co-immunoprecipitation of the wild-type KMT2D, but not of the R5340 mutant, with WDR5. This was not due to differences in expression levels/protein stability between the two KMT2D proteins, as documented by western blot analysis of EGFP in the total cell lysates, indicating that this variant completely abrogates the interaction with WDR5 (Fig. 3B) .
Discussion
Here we report the mutation pattern of KMT2D and KDM6A in a cohort of 505 patients clinically diagnosed as KS-affected, and document the functional role of a subset of KMT2D missense mutations in impairing the protein enzymatic activity.
Overall, the mutation detection rate for KMT2D and KDM6A in our cohort (41%) was lower than that reported in a recent survey (22) . This does not seem to be due to differences in sensitivity as the same Sanger Sequencing approach was used, and may be derived from the involvement of other causative genes, epigenetics mechanisms or yet unrecognized promoter or deep intronic variants affecting normal splicing. Moreover, we cannot exclude that some patients might have been clinically misdiagnosed and present conditions partially overlapping with KS. In view of multiple studies highlighting the clinical and molecular overlap of KS (27) (28) (29) (30) (31) , these samples should be interrogated by using NGS targeted-genes panels focused on components of the histone methylation machinery that are associated to diseases in differential diagnosis with KS.
Our screening revealed 58 different missense variants distributed across the entire length of the KMT2D gene. Indeed, 9 of the 14 representative mutations that were tested in our study had variably reduced histone methylation activity in vitro, including H3K4 mono-, di-and/or tri-methylation. This effect is consistent with the known function of KMT2D as a major mono/dimethyltransferase, which is enriched at enhancer regions and is required for enhancer activation during cell differentiation, as reported in brown adipose tissue and skeletal muscle development (11, 32) , or in mature B cells (33, 34) . Even though recent publications focus on the role of KMT2D as major monomethyltransferase, at least during carcinogenesis (35), KMT2D is also required during oogenesis and early development for bulk histone H3 lysine 4 trimethylation (36) . The ability to modulate H3K4(me3), at active promoters/transcription start sites is important for the regulation of actively transcribed genes (14, 15) , and may reflect in part the formation of promoter-enhancer loops. As a matter of fact, six of the nine KS missense variants with reduced histone methylation activity showed a flawed H3K4(me3) activity in two different assays, emphasizing the role of KMT2D in modulating histone H3K4(me3) in vitro.
Of note, all nine functionally defective missense mutations were localized within the FYRN, WIN and SET domains, and may contribute to the KS phenotypes by interfering with its enzymatic activity in a manner analogous to C-terminal truncating mutations. In contrast, amino acid changes in the N-terminal domain of the protein had minimal effects on H3K4 methylation. Indeed, according to ACMG, most of the amino acid changes in the N-terminal domain of the protein are classified as Likely Benign or Variants Of Unknown Significance ( Table 2 ), suggesting that they may act through different mechanisms or represent neutral events.
The entire KMT2D C-terminal domain (aa 4507-5537) is involved in the interaction with the protein of the WRAD complex (25) , albeit the specific amino acid interaction region is not fully characterized yet. Our study showed that missense variants localized in the C-terminal domains impaired the interaction of KMT2D with other components of its multi-subunit complex, including WDR5, RbBP5 and ASH2L, whereas most of the variants localized within the PHD 4-6 do not affect the interaction. The same C-terminal missense variants also showed altered protein domain structure and free energy interaction levels, suggesting that structural changes occurring in KMT2D may reduce the interaction with the proteins of the WRAD complex.
These data corroborate the hypothesis that the reduced methyltransferase activity is a direct consequence of the lack of multi-protein WRAD complex formation. Consistently, the missense variant R5340Q, localized within the WIN domain, fully abrogated the interaction with WDR5, resulting in a significantly reduced methyltransferase activity.
The classification and interpretation of KMT2D missense variants is a significant challenge in molecular diagnostics and genetic counseling. A number of prediction tools have been implemented in the last years, mainly as support for NGS data. However, in silico analyses should not be considered as conclusive evidence in the assessment of variants of unknown clinical significance. The American College of Medical Genetics and Genomics and the Association for Molecular Pathology Standards and Guidelines for the interpretation of sequence variants (37) recommended that these predictions should be used as support to additional findings, including functional evidence that can prove the pathogenicity of the variants found. Recently, different DNA methylation profiling studies showed that KS patients present a highly specific and univocal DNA methylation signature that has the potential to be used as a diagnostic method for differentiating samples with pathogenic mutations from those with benign variants, and therefore enabling the functional assessment of genetic variants of unknown clinical significance (31, (38) (39) (40) (41) .
Although additional studies will be required to dissect the precise mechanisms underlying the pathogenic role of the missense variants in KS, our data indicate that a subset of them may influence the disease status by affecting: (i) the methyltransferase activity of the protein and (ii) the interaction with the WRAD complex.
The biochemical approaches presented here may provide the basis for the development of diagnostic assays that could be of support to in silico prediction tools, with the advantage of addressing the functional effect of the variant.
Conclusions
This study expands the number of KMT2D and KDM6A mutations that are associated with KS and provides evidence that a number of naturally occurring missense mutations in KMT2D effectively impact KMT2D interaction and H3K4 methylation activity. These data have direct relevance for diagnostic and counseling purposes.
Materials and Methods
Patients and samples preparation
Our study cohort comprised a total of 505 index patients clinically diagnosed as affected by KS (Table 1) , including 202 new cases that were referred to our institution between 2014 and 2017, and 303 patients from previous studies (19, (42) (43) (44) (45) (46) (47) (48) .
Patients were enrolled after obtaining appropriate informed consent by the physicians in charge, and approval by the local ethics committees. KS patients were included following the inclusions criteria as reported (46) . Genomic DNA was extracted from fresh and/or frozen peripheral blood leukocytes of patients and their available family members using an automated DNA extractor and commercial DNA extraction Kits (Qiagen, Germany). Total RNA was extracted from peripheral blood leukocytes using TRIzol reagent (ThermoFisher Scientific, USA) and reverse transcribed using the QuantiTect Transcription kit (Qiagen), according to the manufacturer's instructions.
Sequencing and MLPA of KMT2D and KDM6A
Mutation screening of all 54 coding exons of the KMT2D (MIM #602113, NM_003482.3) gene and 29 coding exons of the KDM6A (MIM #300128, NM_021140.3) gene was performed by PCR amplification and direct sequencing as reported (46) . MLPA analysis was performed as in (47) .
In silico analysis of KMT2D and KDM6A variants 
Protein modeling
Three-dimensional models of the ZF-PHD7 (residues 5059-5137), FYRN (residues 5180-5327) and SET (residues 5398-5537) domains of the human KMT2D protein were obtained employing a combination of threading and homology methods. For each domain, different models were generated using publicly available web servers (58) (59) (60) (61) . Final KMT2D model domains were obtained using the Modeller program and, as templates, the server models (62) . A total of 200 unique models were generated by Modeller for each KMT2D domain. Qmean server (63) was used to assess the quality of the predicted models and KoBaMIN web server (64) was used to carry out the protein energy minimization. The crystal structure of the WIN domain bound to WDR5 was obtained from the RCSB Protein Data Bank (PDB code: 3UVK; residues 5337-5347) (65) . The effects of missense variants on KMT2D domains structure and stability were predicted by the Rosetta Backrub server (66) and FoldX program (67) . Total charge of domains was calculated using the PROPKA program (68) and the electrostatic surface potentials were computed using the Adaptive Poisson-Boltzmann Solver (APBS) software (69) . Models' inspection and model figures were performed using UCSF Chimera (version 1.11) (70).
Plasmids, cell lines and transfection assays
The pFlag-CMV2 FUSION-KMT2D vector [cDNA spanning the PHD4-5-6 domains (amino acids 1358-1572)] and ZF-PHD7-FYRN-FYRC-WIN-SET-post SET domains (amino acids 4507-5537) was a gift of Professor Min Gyu Lee, Department of Molecular and Cellular Oncology, The University of Texas (25) . We sub-cloned this partial KMT2D sequence into the p3XFlag-CMV14 vector (Sigma) using standard procedures. Fourteen representative KMT2D variants identified in our KS cohort that harbor amino acid changes in both N-terminal and C-terminal domains of the protein, including PHD 4-5-6-7, FYRN, WIN and SET domains, have been selected for functional assays: p.E1391K (Likely Pathogenic), p.M1417V (Likely Benign), p.I1428T (Likely Benign), p.S1476C (VOUS), p.Q1522R (Likely Benign), p.F5034V (Likely pathogenic), p.H5059P (Likely Pathogenic), p.T5098P (VOUS), p.G5189R (VOUS), p.W5217R (Likely pathogenic), p.R5340Q (Likely Pathogenic), p.E5425K (Pathogenic), p.R5471M (Likely Pathogenic) and p.Y5510D (Pathogenic). Expression plasmids harboring patient-derived KMT2D missense variants were generated by site-directed mutagenesis according to standard methods.
HEK 293 and 293T cells were cultured in Dulbecco's Modified Eagle Medium with 10% FBS, penicillin (100 U/ml) and streptomycin (100 lg/ml) (Life Technologies). The KMT2D C-terminal ORF was assembled into the pcDNA3-Myc-EGFP vector (71) by PCR site directed amplification using human cDNA and the pFlag-CMV2 FUSION-KMT2D vector as templates respectively. The WDR5 full length ORF was assembled into the p3XFlag-CMV14 vector (Sigma) by RT-PCR amplification reactions using cDNA from HEK 293T cells as template. HEK 293T cells were transiently transfected using the polyethylenimine method, following the published protocols (72) . Cells were harvested 48 h after transfection and used for protein extraction and histone methyltransferase (HMT) assay.
In vitro HMT assay and epigenetic reporter allele
Partially purified FLAG-KMT2D wild-type and mutant derivative proteins were extracted from transfected HEK 293T cells by co-IP buffer (50 mM Tris, pH 7.5, 250 mM NaCl, 1% Triton X-100, 1 mM EDTA), followed by overnight incubation with EZview TM Red Anti-FLAG Affinity Gel (Sigma) at 4 C and final elution in BC100 buffer (20 mM Tris, pH 7.5, 10% glycerol, 0.2 mM EDTA, 1% Triton X-100, 100 mM NaCl) containing FLAG peptide (Sigma). KMT2D protein amounts were quantified by Coomassie staining and immunoblot analysis using mouse monoclonal FLAG antibodies. Enzymatic activity against HeLa nucleosomes was measured following a published method (25) . Briefly, equal amounts of wild-type or mutant FLAG-KMT2D proteins were incubated at 37 C for 4 h with HeLa nucleosomes (Reaction Biology) in KMT buffer (50 mM Tris, pH 8.5, 100 mM KCl, 5 mM MgCl 2 , 10% glycerol, 4 mM DTT) supplemented with S-adenosyl methionine (New England BioLabs). Reactions were stopped by adding equal volumes of 2Â Laemmli buffer and heated at 100 C for 5 min before loading onto Tris-glycine 4-20% gradient gels. All assays were performed at least two times independently. The epigenetic reporter allele, a kind gift from Dr Hans T. Bjornsson (McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore), was used as described (23) .
Co-immunoprecipitation assay and western blotting analysis
Co-immunoprecipitations were performed using Dynabeads magnetic beads (ThermoFisher Scientific) and EZview TM Red
Anti-FLAG Affinity Gel (Sigma) following the manufacturer's instructions. Complexes were analyzed by Western blot using the indicated antibodies. Protein extracts were resolved on NuPAGE Tris-acetate 3-8% gels (for KMT2D) or Tris-glycine 4-20% gels (for histone H3) (ThermoFisher Scientific) and transferred to nitrocellulose membranes (GE Healthcare) according to the manufacturer's instructions. Antibodies used were mouse monoclonal antibody to a-tubulin (clone DM1A, Sigma), rabbit polyclonal antiH3K4me1 (Abcam), anti-H3K4me2 (Active Motif), anti-H3K4me3 (Abcam), rabbit monoclonal anti-Histone H3 (clone D1H2, Cell Signaling Technology), mouse monoclonal anti-Flag (Sigma cat# F3165), rabbit monoclonal anti GFP (Santa Cruz), rat monoclonal anti-HA (Roche), mouse monoclonal anti Myc (Roche), rabbit polyclonal anti Ash2 (Bethyl) and rabbit polyclonal anti RbBP5 (Bethyl). Horseradish peroxidase conjugated anti-mouse (Santa Cruz) or anti-rabbit (Santa Cruz) antibodies, and the ECL chemiluminescence system (GE Healthcare) were used for detection. ImageJ software (http://imagej.nih.gov/ij/; date last accessed 5 July 2018) was used to quantify band signal intensity. Values are expressed as fold differences relative to the wild-type protein sample, set at 1, after normalization for the loading control.
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